In the preclinical models of preeclampsia, both drugs could mitigate the expressions of endothelial dysfunction markers, including vascular cell adhesion molecule-1 and endothelin-1, and reduce the secretion and expression of sFlt-1 (anti-angiogenic factor) from primary cytotrophoblasts, but only esomeprazole magnesium hydrate reduced sFlt-1 secretion from primary human umbilical vein endothelial cells [27]. This evidence concerns the gene EDN1 and preeclampsia.